Aphria delivers 1,500 bottles of Rideau oil to its subsidiary ABP to support the advancement of clinical medical cannabis research.
The Company also completes the first shipment of medical cannabis to Malta-based subsidiary ASG Pharma.
LEAMINGTON, ON, Oct. 15, 2018 /CNW/ – Aphria Inc. today announced that it has completed its first shipment of cannabis oil to its Argentina-based subsidiary ABP, S.A. (“ABP” or the “Argentinean Company“), a pharmaceutical import and distribution company. In accordance with a previously announced supply agreement, the Company delivered 1,500 bottles of Aphria’s renowned Rideau CBD oil, which were provided to Hospital de Pediatria Garrahan (“Hospital Garrahan” or the “Hospital“), a leading pediatric hospital located in Buenos Aires, for use in a clinical study focused on treating refractory epilepsy in children.
Aphria acquired ABP last month when the Company closed its acquisition of LATAM Holdings Inc. (“LATAM Holdings“), expanding the Company’s global footprint to include a leading presence in Latin America and the Caribbean. “Argentina will play a foundational role as Aphria cements its leadership in medical cannabis throughout the region,” said Vic Neufeld, Chief Executive Officer of Aphria. “Aphria and ABP, in close partnership with the Argentinean government, continue to advance opportunities for medical cannabis in the country, including the potential for in-country cultivation. We are also proud to support the critical and necessary research being undertaken by Hospital Garrahan on the treatment of refractory epilepsy in children with our Rideau CBD oil.”
As a well-established and successful pharmaceutical import and distribution company, ABP was granted the first permit issued by the Argentina Ministry of Health for the import of pharmaceutical-grade medical cannabis. The Argentinean Company has been forging a reputation as a champion for the research and clinical study of medical cannabis, including through its partnership with the Hospital, one of the most recognized and credible medical institutions in South America.
The clinical study, which involves 100 patients and will be conducted over 2.5 years, will be one of the foundational global scientific and medical studies of its kind focused on treating refractory epilepsy in children. Medical researchers will conduct a pharmacokinetics study of the Rideau product, which will help optimize the ideal dosage in future patients. Top neurologists and pediatric specialists from around the country will participate and, with the support of ABP and Aphria, will receive training and support to be able to train and educate a network of doctors throughout Argentina.
Aphria completes the first shipment of medical cannabis to ASG Pharma
The Company also announced it has completed its first shipment of cannabis oil to its Malta-based subsidiary ASG Pharma Ltd. (“ASG“). The majority-owned subsidiary received the first import certificate for medical cannabis issued by the Government of Malta’s Ministry of Health and will use this first delivery of Aphria’s renowned Rideau CBD oil to perform analytical testing and research.
“This marks another important milestone as we continue to execute on our strategic expansion plans in Europe and around the world,” added Neufeld. “Our EU-GMP certified lab in Malta will play an important role for the Company in accessing cannabis markets across the continent, and it will stand as a leading European centre for the research and testing of medical cannabis and derivative products.”
ASG’s facilities, which are undergoing a multi-million-euro upgrade of its processing and manufacturing capabilities, will serve as Aphria’s hub for importing cannabis resin and dried flower for processing, packaging and distribution of EU-GMP certified cannabis products throughout large parts of Europe
